Both in Medical Labs
BioNexus Gene Lab vs Sera Prognostics
Over the past year BGLC returned −79.5% and SERA returned −45.9%; their daily moves had a correlation of 0.16.
BGLC −79.5% SERA −45.9%Growth of $1, one year, split-adjusted
| Metric | BGLC | SERA |
|---|---|---|
| Price | $1.06 | $2.03 |
| Market cap | $3.1M | $80.1M |
| Today | −5.95% | −0.98% |
| 1 month | −16.3% | +1.0% |
| 6 months | −48.4% | +2.0% |
| Year to date | −73.1% | −31.2% |
| 1 year | — | −45.7% |
| Revenue growth (YoY) | −96.6% | +76.5% |
| Gross margin | 17.0% | −66.7% |
| Net margin | −376.1% | −30463.3% |
| P/E (TTM) | — | — |
| Price / sales | 1.0× | 1,144.0× |
| Net cash | $1.2M | $46.4M |
| Dividend yield | — | — |
| Volatility (60d) | 66.4% | 34.0% |
| Short % of float | 0.5% | 0.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).